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The Immunologic Staging of Chronic 
Active Hepatitis B Patients in Hawaii 
Nathaniel Ching MD*, James Lumeng MD**, Eugene Pon MD++, Clara Y. Ching PhD+ 
The hepatitis B antigen/antibody levels and natural killer cell 
activity status of chronic hepatitis B patients identified by the 
Hawaii State Department of Health were evaluated to select 
chronically infected hepatitis B patients for interferon therapy 
and to determine possible immunodeficiencies. The presence of 
hepatitis Be antigen denotes active replication of the virus. 
Ninety-five patients were studied: 17/95 (18%) had chronic 
active hepatitis B, 71/95 (75%) were hepatitis B carriers and 7/ 
95 (7%) had seroconverted. NK activity to the erythroleukemia 
K562 cell and virus-infected HSV-1 cell of the chronic active and 
carrier population (P<.05) were lower than that of the control 
population and those who had spontaneously seroconverted. Of 
this population 18% were identified with active viral infection and 
would be candidates for interferon therapy. 
Introduction 
Infection from the hepatitis B 
virus (HBV) presents Hawaii 
with a major public health prob-
lem because of its large immi-
grant population from Asia and 
the South Pacific. The HBV-
carrier rate in Hawaii is estimated 
at 2% to 3% as compared to the 
overall U.S. rate of 0.5%. 1 
Hepatitis B 
Carriers 
piece in the plus strand exists outside of the virus as a viral 
fragment, HBe antigen (HBeAg). Therefore, if HBeAg is de-
tected, there is active HBV replication occurring in hepatocytes. 
HBV carriers are patients who demonstrate persistent hepatitis 
B surface antigenemia. The presence of active viral replication 
in hepatocytes will be indicated by finding serologic HBe 
antigen. Carriers do not have antibody to the HBsAg. 
The immunomodulating and anti-viral effect of interferon 
(IFN) has been demonstrated to be effective in up to 50% of 
chronic, active hepatitis B patients.2-6 The FDA approved inter-
feron therapy for HBeAg-positive patients in July 1992. 
NK cells, large granular lymphocytes, are considered impor-
tant in natural immunosurveillance in cancer and certain infec-
tious diseases. 10 NK-cell cytotoxicity does not require prior 
Chronic Active Hepatitis 
Negative for 
Hepatitis B 
Markers 
exposure to antigen and is not 
MHC restricted. We evaluated 
the hepatitis B antigen/antibody 
levels and immunological sta-
tus of volunteers from the reg-
istry of the Hawaii Department 
of Health to select hepatitis B 
patients for long-term inter-
feron therapy and to determine 
the possible deficiencies in 
natural killer cell activity in 
these patients. HBV is a double-stranded 
DNA virus with 3 different pro-
tein antigenic markers: Hepatitis 
B core antigen (HBcAg), hepati-
tis B surface antigen (HBsAg), 
Figure 1 Categorization of study population. Three groups were delineated. 
The chronic hepatitis B group will be amenable to interferon therapy. Methods and Material Patient Population.-The 
and the core-related antigen, hepatitis Be or (HBeAg). 2 HBsAg 
is found on the surface or the envelope of HB V. The inner coat, 
the capsid, is a single core protein surrounding the viral DNA 
where HBcAg is displayed.2 Although HBV is doubled-stranded, 
the plus strand is shorter than the minus strand. The missing 
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Epidemiology Branch of the 
Hawaii State Department of Health contacted patients with 
chronic hepatitis B who were registered in its HBV program to 
obtain patient permission to be retested and staged for possible 
therapy with interferon alpha-2b. Patients replying in the affir-
mative were contacted and scheduled for evaluation of their 
hepatitis Be antigen/antibody status and retesting of their hepa-
titis B surface antigen/antibody status and serum ALT(SGPT) 
levels. Information on birthplace, ethnicity and other standard 
demographic data were obtained from each patient; all patients 
signed informed consent forms. HBsAg and antibody to HBsAg 
(anti-HBs) were performed at St. Francis Medical Center, w bile 
HBeAg and anti-HBe were performed by SmithKline Beecham 
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Laboratories, both using diagnostic materials by Abbott Labo-
ratories, North Chicago, Illinois. 
Immunological Evaluation. -Natural killer cell activity (NK) 
to the K562 erythroleukemia cell and herpes simplex virus-
infected fibroblast cell were analyzed in the first 50 patients. 
Standard chromium-release cytotoxic assays were performed 
with Ficoll-Hypaque-separated peripheral blood mononuclear 
cells as previously reported. 7' 9 The controls were healthy volun-
teers who were recruited from the laboratory, medical center and 
community organizations. 
Statistical Analyses.-Data was analyzed utilizing the PC 
Stat program from Human System Dynamics, Northridge, Cali-
fornia. NK activity was analyzed using the Mann-Whitney non-
parametric test. Data is reported as the mean ±1 SD. 
Results 
This report defines chronic, active hepatitis B patients as 
thosewithHBsAgandHBeAg, withoutanti-HBeandanti-HBs. 
Chronic hepatitis B carriers are defined as those patients who are 
HBsAg-positive, anti-HBs negative and anti-HBe positive in 
response to their hepatitis infection. (Table 1) Ninety-five pa-
tients agreed to be considered for the study: 17/95(18%) had 
chronic, active hepatitis B, 71195 (7 5%) were hepatitis B carriers 
and 7/95 (7%) had no remaining evidence of hepatitis B markers. 
(Figure 1) 
Sixty-one women and 27 men were positive for hepatitis B. 
The same women-to-men ratio was observed in the chronic, 
active and carrier groups. The chronic, active hepatitis B group 
was younger than the carrier group, averaging 32 years of age as 
opposed to the carrier group, which averaged 39 years, P=<.04. 
Table 1 Staging Hepatitis 8 
Population H8eAg anti-H8e H8sAg 
Chronic Active 
Hep 8 + + 
Chronic Hep 8 
(Carrier) + + 
Table 2. NK activity of chronic Hepatitis B Patients (X±SD) 
Control 
Hep 8-Active 
Hep 8-Carrier 
N 
31 
12 
23 
K562 
20% 
(lu) 
100±76 
78±55 
69±54* 
N 
31 
10 
23 
anti-H8s 
HSV-1 
20% 
(lu) 
48±35 
48±45 
34 ± 33** 
(lu): Mean lytic units is defined as the number of effector cells/1 OE+ 7 required 
to achieve 20% lysis of the target cells of NK activity of blood lymphocytes. 
Mann-Whitney Non-parametric Analysis. 
*p<.05 **p<.02 
-
The major ethnic distribution of the entire group studied 
consisted of the following: Filipino (33%), Chinese (17%), 
Vietnamese (12.5%), Japanese (10%), mixed Asian (8%), and 
Korean (6%). Most of the Filipinos and Vietnamese were not 
born in the United States; some of the Chinese and Japanese 
were born in Hawaii. These same 5 races predominated in the 
active hepatitis group. No active patients were identified in the 
Samoan, Polynesian, Laotian, Caucasian or mixed ethnic groups. 
We could not accurately determine when the patients were 
initially infected. 
SerumAL T (SGPT) levels were elevated in all except 2 of the 
chronic active hepatitis B patients, X (mean)= 100 ±128. Only 
3/71 (9%) hepatitis B carriers had ALT level> 1.3x high normal 
value. 
NK Activity.-Mean values ofNKactivity (lytic units in 20% 
Kill) to the K562 erythroleukemia cell line were 100 ±82lytic 
units in the control individuals, but lower, 78 ±55 lytic units in 
the chronic active hepatitis B and 69 ±541 ytic units in the carrier 
hepatitis B group. (Table 2) A significant difference was noted 
with non-parametric analysis for NK (K562) activity (P<.05) 
and for NK (HSV-1) activity (P<.02). The patients who had 
spontaneously seroconverted had NK(K562) activity of 146 
± 72, not significantly different from that of the controls. 
Discussion 
Previously diagnosed chronic hepatitis B patients were 
screened to delineate patients who would qualify for therapy 
withrecombinantinterferonalpha-2b. Wehaveidentifiedahigh 
18% incidence of chronic active hepatitis Bin this population. 
This is the stage of the disease that has been reported to respond 
to therapy with long-term interferon alpha-2b. 
The typical patient in this study was a young woman with 
responsible employment or who was raising a young family. 
Also of significance was the preponderance of patients of Asian 
descent who primarily were immigrants and some of the Chi-
nese and Japanese who were born in Hawaii. 
Young hepatitis B patients should be treated to prevent the 
development of cirrhosis and/or hepatoma in the future. The 
State of Hawaii has developed a successful hepatitis B vaccina-
tion program in the newborn population. Efforts and attention 
should also be directed to immigrants arriving in Hawaii from 
areas of the world endemic for HBV. 
As licensed by the FDA, interferon is administered at 5 
million units daily or 10 million units 3 times a week for 4 
months. Fatigue, a side-effect of interferon at these levels, 
generally is significant, which might influence the productivity 
of these patients over long periods. Therapeutic trials must be 
designed to allow these patients to function normally. 
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rate was 50% should perforation occur. Cancer 
Research Center of Hawaii director, Brian 
Issell, reported that during his 5 years at 
Stanford, the incidence of perforation had been 
very low. Dennis wondered if surgery was 
contraindicated anyway because of the omen-
tal and peritoneal adenopathy. Scott could not 
commit himself without first reviewing the 
scans personally. 
Moderator Ken Sumida summarized: "Ap-
parently everyone will go along with chemo-
therapy without a total gastrectomy." For once, 
everyone was in accord. 
Novel treatment 
(By James Watt Toronto, Punch, June 1993) 
A long time ago when I was an intern at a 
Toronto teaching hospital, a patient came to 
emergency with a fish bone stuck in her throat. 
The ENT staff physician on call was contacted 
and the intern was told to take the patient to the 
ENT operating room. 
Just outside emergency was a corridor with 
a gently sloping ramp leading to another part of 
the hospital where the ENT OR was located. 
At the top of the ramp, the intern lost control 
of the wheelchair, and it hurtled down the 
ramp. At the bottom of the ramp, one of the 
wheels of the wheelchair caught on the door-
way and the patient was thrown to the ground. 
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The patient immediately coughed up the fish 
bone. 
With great presence of mind the intern said, 
"You're awfully lucky, lady-usually we have 
to do this 2 or 3 times before we get it out." 
Oncology conference 
(December9, 1993) 
Former KMC pathologist emeritus Grant 
Stemmerman (Now working out of Cincin-
nati) spoke on his favorite subject "Intestinal 
metaplasia and gastric cancer." 
Oncologist Kaye Kawahara presented a 
52-year-old Filipino man who had stopped 
smoking 10 years before but had a T3 lesion of 
the larynx when worked up for persistent 
hoarseness by ENT Meredith Pang. Radiolo-
gist Howard Arimo to showed CT scans of the 
lesion. Moderator Lois Mastrofrancesco 
asked Stemmy the probability of cancer after 
quitting smoking more than 10 years. Stemmy 
remarked that the probability curve was still 
quite high. He added, "Filipinos have the low-
estcancer incidence in Hawaii because of their 
high vegetable diet. It is remarkable that he 
does have cancer." Kaye explained that this 
Filipino man was a robust meat eater and did 
not like his veggies. 
Lois, a quality-of-life advocate, explained 
that traditionally lamgeal Ca was treated with 
Classified Notices 
To place a classified notice: 
HMA members: Please send signed and typewrit-
ten ad to HMA office. As a benefit of membership, 
HMA members may place a complimentary one-
time classified ad on a space-available basis. 
Nonmembers: Please call 536-7702 for a non-
member form. Rates are $1.50 a word with a mini-
mum of 20 words or $30. Not commissionable. 
Payment must accompany written order. 
Employment 
Medical Director position available at Kahi 
Mohala. Board-certified psychiatrist w/child and 
adolescent experience preferred. Direct delivery of 
behavior health services. Send resume and salary 
requirements to Kahi Mohala, 91-2301 Ft. Weaver 
Road, Ewa Beach, Hawaii 96706. 
Practice for Sale 
General Practice for sale. Very easy terms. Phone 
(808) 533-1844. 
-
HAWAII MEDICAL JOURNAL. VOL. 53, FEBRUARY 1994 
49 
laryngectomy followed by chemo orradiation; 
now the trend is larynx preservation when 
possible viz chemo and radiation first and if 
this fails, laryngectomy. The survival curves 
are the same. 
Do unto others 
(James Fisher, Jr.) 
.&. "To have a friend, you must be a friend, 
starting with yourself." 
.&. "The greatest virtue is kindness. You can't 
love everyone, but you can be kind to every-
one." 
.&. "Be enthusiastic. Nothing of consequence 
was ever achieved without enthusiasm." 
.&. "Be positive. Positive people attract others 
while negative people repel." 
(From Readers Digest, June 1993) 
Services 
Commercial/Residential Design. Nostalgic 
hawaiian design for home and offi~ew building, 
remodeling, and interiors. Victor Weeks Design 
Phone 988-5430. 
MLEr5 PLAY DOCTOR. I'LL 5E THE DOCTOR 
AND YOU 5E THE MALE NUR5E." 
